ArticleAnnals of clinical and translational neurology2026
Blood RNA Biomarker Signatures for Early Diagnosis and Prognosis in Ischemic and Hemorrhagic Stroke: The IBIS-CT1 Study.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo evaluate the expression of nine blood RNA biomarkers in a clinical trial based on genes previously identified in an experimental monkey model of stroke for diagnosis feasibility and prognostication.
methodsIBIS-CT1 was a prospective longitudinal study enrolling patients with ischemic stroke (IS) or intracerebral hemorrhage (ICH) within 6 h of onset, compared with healthy controls (HC). Blood samples were collected at < 6 h (early), 12 h, 24 h, 48 h, 7 days, and 3 months. Target RNAs were quantified using reverse-transcription PCR or digital droplet PCR. Clinical severity and disability were assessed by NIHSS at admission and the modified Rankin Scale (mRS) at 3 months.
resultsTwenty HC, 20 IS, and 20 ICH patients were included. Compared with HC, IS patients showed significant early upregulation of genes ADM, DUSP1, HMOX1, HSPA1B, LDLR, and PTGS2 (all p ≤ 0.0002) and downregulation of BAG3 (p < 0.0001). Similar patterns were observed in ICH, with higher expression levels than in IS. In IS, higher NIHSS scores correlated with early upregulation of ADM, DUSP1, HMOX1, PTGS2, and GOS2, while lower BAG3 expression associated with poorer 3-month outcomes. Combined gene expression discriminated stroke from controls with an AUC of 0.914 (95% CI, 0.84-0.98).
interpretationDistinct blood gene-expression signatures differentiate stroke from controls and predict functional outcome, supporting their potential as diagnostic and prognostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.